Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Neural Regeneration Research|May 5, 2017
Neuromelanin, one of the most overlooked molecules in modern medicine, is not a spectatorRobert L Haining, Cindy Achat-Mendes
Pharmacology & Therapeutics|February 3, 2007
Cytochrome P450-catalyzed pathways in human brain: metabolism meets pharmacology or old drugs with new mechanism of action?Robert L Haining, Mari Nichols-Haining
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 6, 2006
Expression, purification, and characterization of mouse CYP2d22Ai-Ming Yu, Robert L Haining
Neurochemical Research|September 25, 2016
Saturation Binding of Nicotine to Synthetic Neuromelanin Demonstrated by Fluorescence SpectroscopyRobert L Haining, Travis M Jones, Aubrey Hernandez
The Journal of Pharmacology and Experimental Therapeutics|November 20, 2002
Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoformsAiming Yu, Byron M Kneller, Allan E Rettie, et al.
Biochemical Pharmacology|August 23, 2005
CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoinTina M Bland, Robert L Haining, Timothy S Tracy, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 8, 2008
Expression and functional analysis of CYP2D6.24, CYP2D6.26, CYP2D6.27, and CYP2D7 isozymesWei-Yan Zhang, You-Bin Tu, Robert L Haining, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 21, 2002
(+)-N-3-Benzyl-nirvanol and (-)-N-3-benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19Hisashi Suzuki, M Byron Kneller, Robert L Haining, et al.
Biochemical Pharmacology|May 8, 2004
Differential activation of CYP2C9 variants by dapsoneMatthew A Hummel, Leslie J Dickmann, Allan E Rettie, et al.
Pageof 2